Motley Fool Wealth Management’s Genomic Health, Inc. GHDX Stock Holding History

Motley Fool Wealth Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-156,919	Closed	-$5.37M	–	150
2017 Q4	$5.37M	Buy	156,919 +8,972	+6%	+$286K	0.41%	74
2017 Q3	$4.75M	Buy	147,947 +7,466	+5%	+$235K	0.4%	72
2017 Q2	$4.57M	Buy	140,481 +11,236	+9%	+$356K	0.41%	72
2017 Q1	$4.07M	Buy	129,245 +6,106	+5%	+$181K	0.39%	77
2016 Q4	$3.62M	Buy	123,139 +3,812	+3%	+$116K	0.39%	81
2016 Q3	$3.45M	Sell	119,327 -3,691	-3%	-$103K	0.36%	79
2016 Q2	$3.19M	Buy	123,018 +6,622	+6%	+$176K	0.35%	84
2016 Q1	$2.88M	Buy	116,396 +10,216	+10%	+$280K	0.34%	86
2015 Q4	$3.74M	Buy	106,180 +23,322	+28%	+$625K	0.44%	65
2015 Q3	$1.75M	Sell	82,858 -60,899	-42%	-$1.57M	0.23%	114
2015 Q2	$4M	Sell	143,757 -30,532	-18%	-$861K	0.64%	47
2015 Q1	$5.33M	Buy	174,289 +101,557	+140%	+$3.23M	1.11%	25
2014 Q4	$2.33M	Buy	+72,732	New	+$2.37M	1.36%	28

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Motley Fool Wealth Management's GHDX Position: Q1 2018 in Review

Motley Fool Wealth Management sold out of Genomic Health, Inc. (GHDX) in Q1 2018, closing a stake of 156,919 shares — an estimated $5.37M sold.

Motley Fool Wealth Management first reported a position in GHDX in Q4 2014 and held it in 13 quarters. The position peaked at $5.37M in Q4 2017. 134 funds tracked by Wall St. Rank hold GHDX as of Q1 2018.

Motley Fool Wealth Management reported no remaining Genomic Health, Inc. position as of Q1 2018 after selling out during the quarter.
Motley Fool Wealth Management sold 156,919 Genomic Health, Inc. shares in Q1 2018, an estimated $5.37M.
Motley Fool Wealth Management first reported a position in Genomic Health, Inc. in Q4 2014 and held it in 13 quarters.
Motley Fool Wealth Management's Genomic Health, Inc. position peaked at $5.37M in Q4 2017.
134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2018.

Based on Motley Fool Wealth Management's 13F filing for Q1 2018, filed 4 May 2018.